Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Cost Effectiveness and Resource Allocation

Fig. 1

From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Fig. 1

Structure of the Markov model. a Follow-up treatment states: duplicated for each follow-up treatment. Patients not responding in the first 6 months of follow-up treatment move to the next treatment in the sequence. b Reason for discontinuation (lack of efficacy or adverse events) determined by the probabilities after leaving treatment health state

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us